AC Immune
Erika Borcel is a Clinical Project Manager at AC Immune, responsible for the setup and management of Phase II clinical trials in neurodegenerative diseases, including the operational implementation of wearable devices. Previously, Erika served as a Guest Lecturer in Digital Ethics at Université de Fribourg and held various roles at CHUV | Lausanne university hospital, including Clinical Project Coordinator and Project Manager for the EBRAINS platforms. With a strong background in neuroscience, Erika's experience includes postdoctoral research positions at EPFL and several universities in Madrid, focusing on neurobiology, behavior, and clinical trials. Erika holds a Doctorate in Biology from Universidad Complutense de Madrid, complemented by a Master's and Bachelor's in Neurobiology and Biology.
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.